Condition: Kidney Cancer · Renal Cell Carcinoma Metastatic · Drug Toxicity · Sponsor: Niels Fristrup
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients. Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.
This description comes directly from the study's public registry record.
Niels Fristrup, MD, PhD · +4520914161 · niels.fristrup@rm.dk
Jakob N Henriksen, MD · +4540438804 · jakob.n.henriksen@oncology.au.dk
Always discuss trial participation with your own doctor first.
| Department of Oncology, Aarhus University Hospital | Aarhus, Danmark, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04659343